To view the fulltext, please log in
To view the pdf, please log in
The H63D mutation in the hemochromatosis gene (HFE) has recently been considered as a risk factor in Alzheimer`s disease (AD) with advancing age at onset of the disease, independently of the apolipoprotein E (ApoE) ε4 allele effect. We examined the distribution of the H63D mutation and ApoE genotypes as a function of age at AD onset in 328 patients with sporadic AD. Our data show that the mutant H63D allele potentially interacts with the ApoE ε4 allele to significantly reduce age at onset of AD compared to ApoE ε4 carriers alone, but has no effect on age at onset in ApoE ε4 non-carriers.
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Lynch T, Cherny RA, Bush AI: Oxidative processes in Alzheimer’s disease: The role of Aβ-metal interactions. Exp Gerontol 2000;35:445–451.
- Smith MA, Harris PLR, Sayre LM, Perry G: Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866–9868.
- Rao KSJ, Rao RV, Shanmugavelu P, Menon RB: Trace elements in Alzheimer’s disease brain: A new hypothesis. Alzheimers Rep 1999;2:241–246.
- Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y: Association of transferrin C2 allele with late-onset Alzheimer’s disease. Hum Genet 1997;101:126–129.
- Kim KW, Jhoo JH, Lee JH, Lee DY, Lee KU, Youn JY, Woo JI: Transferrin C2 variant does not confer a risk for Alzheimer’s disease in Koreans. Neurosci Lett 2001;308:45–48.
- Hussain RI, Ballard CG, Edwarson JA, Morris CM: Transferrin gene polymorphism in Alzheimer’s disease and dementia with Lewy bodies in humans. Neurosci Lett 2002;317:13–16.
- Roy CN, Andrews NC: Recent advances in disorders of iron metabolism: Mutations, mechanisms and modifiers. Hum Mol Genet 2001;10:2181–2186.
- Lyon E, Frank E: Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem 2001;47:1147–1156.
- Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C: The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease. Neurobiol Aging 2001;22:563–568.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer Disease. Neurology 1984;24:939–944.
- Sánchez M, Bruguera M, Bosch J, Rodés J, Ballesta F, Oliva R: Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 1998;29:725–728.
- Moalem S, Percy ME, Andrews DF, Kruck TPA, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC: Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000;93:58–66.
- Jolivalt C, Leininger-Muller B, Bertrand P, Herber R, Christen Y, Siest G: Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic Biol Med 2000;28:129–140.
- Tamaoka A, Miyatake R, Matsuno S, Ishii K, Nagase S, Sahara N, Ono S, Mori H, Wakabayashi K, Tsuji S, Takahashi H, Shoji S: Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer’s disease. Neurology 2000;54:2319–2321.
- Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA: Apolipoprotein E modulates Alzheimer’s Aβ (1–42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 2002;924:90–97.